ONCO BTA Stock Overview

A biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. More details

ONCO BTA fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 78.4% below our estimate of its fair value

Revenue is forecast to grow 57.67% per year

Earnings have grown 6.5% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue (SEK35M)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Oncopeptides AB (publ) Competitors

Medivir

OM:MVIR

SEK 316.3m

Saniona

OM:SANION

SEK 900.7m

Alzinova

OM:ALZ

SEK 312.1m

Nanologica

OM:NICA

SEK 151.1m

Price History & Performance

Summary of share price highs, lows and changes for Oncopeptides
Historical stock prices
Current Share Price	SEK 3.00
52 Week High	SEK 3.00
52 Week Low	SEK 2.35
Beta	-0.48
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	20.48%

Recent updates

Shareholder Returns

	ONCO BTA	SE Biotechs	SE Market
7D	11.5%	-0.3%	-2.2%
1Y	n/a	6.2%	6.1%

Return vs Industry: Insufficient data to determine how ONCO BTA performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how ONCO BTA performed against the Swedish Market.

Price Volatility

Is ONCO BTA's price volatile compared to industry and market?
ONCO BTA volatility
ONCO BTA Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.1%
Market Average Movement	5.6%
10% most volatile stocks in SE Market	11.3%
10% least volatile stocks in SE Market	3.2%

Stable Share Price: ONCO BTA has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ONCO BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	57	Sofia Heigis	www.oncopeptides.com/sv

Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden

Oncopeptides AB (publ) Fundamentals Summary

How do Oncopeptides's earnings and revenue compare to its market cap?
ONCO BTA fundamental statistics
Market cap	SEK 717.26m
Earnings (TTM)	-SEK 249.11m
Revenue (TTM)	SEK 35.22m

20.4x

P/S Ratio

-2.9x

P/E Ratio

Is ONCO BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ONCO BTA income statement (TTM)
Revenue	SEK 35.22m
Cost of Revenue	-SEK 1.08m
Gross Profit	SEK 36.30m
Other Expenses	SEK 285.41m
Earnings	-SEK 249.11m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 30, 2024

Earnings per share (EPS)	-1.14
Gross Margin	103.06%
Net Profit Margin	-707.30%
Debt/Equity Ratio	187.5%

How did ONCO BTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/05/15 23:58
End of Day Share Price	2024/05/13 00:00
Earnings	2023/12/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncopeptides AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Erik Hultgård	Carnegie Investment Bank AB
Patrik Ling	DNB Markets
Robert Burns	H.C. Wainwright & Co.

Oncopeptides OM:ONCO BTA Stock Report